Tag: Levobupivacaine

The tragic cardiotoxicity associated with bupivacaine has led to the development of safer, long-acting agents. For patients where cardiac risk is a concern, a crucial question arises: **What is the least cardiotoxic local anesthetic?** The answer is primarily ropivacaine and levobupivacaine, which were engineered to minimize adverse cardiac effects compared to older agents.

Of all local anesthetics, bupivacaine is associated with the highest incidence of cardiac toxicity and is among the most challenging to treat in cases of systemic toxicity [1.2.1, 1.2.3, 1.2.6]. This article explores which local anesthetic drug has the highest cardiotoxicity and why.

In the late 1970s, reports of severe cardiotoxicity and fatal outcomes associated with bupivacaine led to an intense focus on understanding its pharmacological properties and developing safer alternatives. Levobupivacaine emerged as a safer option due to fundamental differences in its chemical structure, which significantly reduces the risk of cardiac adverse effects compared to the racemic bupivacaine mixture.

Anawin Injection, containing the active ingredient Bupivacaine or its isomer Levobupivacaine, is a widely used local anesthetic [1.3.3, 1.2.2]. So, what is the use of Anawin Injection? It is primarily administered to numb specific areas of the body for surgical procedures and pain relief [1.2.5].